Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The delivery of clinical care, research, and education in neuro-rehabilitation in Oxford will be revolutionised by an innovative partnership with Quinnipiac University, Hartford, USA.

Quinnipiac students Sean Pennetti and Evan Jameyfield

The Nuffield Department of Clinical Neurosciences (NDCN) at the University of Oxford, and the Oxford University Hospitals NHS Foundation Trust, are already known for basic and translational neuroscience research. But delivery of neuro-rehabilitation services is fragmented, which limits clinical care and research opportunities, especially for patients with progressive MS where the needs are greatest. Quinnipiac has a nationally respected neuro-rehabilitation programme, with a comprehensive clinical care model and access to a vast longitudinal clinical, biofluid, and imaging repository for research.

The aim is for Oxford to become a world-leading centre of excellence in restorative neuroscience.
- Associate Professor Gabriele De Luca

The partnership has been negotiated by Associate Professor Gabriele De Luca, Director of Clinical Neurosciences Undergraduate Education in the Medical Sciences Division at the University of Oxford. Together with senior leadership in NDCN, he has secured $3.6m for Phase One of the partnership. Contributions have been made by Quinnipiac University, Trinity Health New England, and Oxford University Hospitals NHS Foundation Trust.

 

This money will fund a five-year medical student exchange programme starting this July. The four medical school participants, who were selected through a competitive application process, are Sean Pennetti and Evan Jameyfield from Quinnipiac and Lucy Kirkwood and Matthew Williams from Oxford. In September, Sam Baskharoun and Vidhi Rao from Quinnipiac and James Towner and Hibatullah Abuelgasim of Oxford will take part in the programme.

Dr Robert Krug, the William and Barbara Weldon Chair and director of the Institute for Rehabilitation Medicine at the Netter School at Quinnipiac, will join Dr De Luca in leading the exchange programme.

‘This the first phase of a partnership that we hope will result in a long-term sustainable relationship between Quinnipiac, Oxford and Mount Sinai,’ said Krug, who also is president and executive medical director of Mount Sinai Rehabilitation Hospital. ‘Not only is this an incredible opportunity for medical students at the Netter School and the University of Oxford, but we believe both institutions will benefit from the collaboration.’

Future plans include the funding of two research fellowship posts. It is envisaged that Quinnipiac’s clinical team will provide rehabilitation expertise so that Oxford can create a comprehensive care centre for progressive MS that integrates clinical care, research, and education.

Similar stories

Royal Commission Industrial Fellowship for Andrei-Claudiu Roibu with F. Hoffmann-La Roche Ltd

Mapping brain network activity from structural connectivity using deep learning

Researchers awarded Wellcome Innovator Grant to investigate role of brainstem nucleus in human consciousness

Researchers at Oxford University have received a prestigious Wellcome Innovator Grant for investigating the role of the pedunculopontine nucleus (PPN) – a brainstem nucleus – in human consciousness.

Blood lipoprotein levels linked to future risk of amyotrophic lateral sclerosis

Greater understanding of the role of lipoproteins could support screening and efforts to develop treatments.

Alexander Davies wins top UKRI Future Leaders Fellowship

Alex is one of eight Oxford University academics who have been awarded significant financial funding from the UKRI Future Leaders Fellowships Scheme

New study on link between autoimmunity and pain

Patients with autoantibodies which target neuronal proteins can have pain as an under-recognised clinical manifestation.